Pulse Biosciences Inc (PLSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulse Biosciences Inc (PLSE) has a cash flow conversion efficiency ratio of -0.141x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.04 Million) by net assets ($92.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pulse Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Pulse Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Pulse Biosciences Inc (PLSE) total liabilities for a breakdown of total debt and financial obligations.
Pulse Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulse Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Sunshine Laser & Electronics Technology Co Ltd
SHE:300227
|
-0.059x |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
0.034x |
|
Evolv Technologies Holdings Inc
NASDAQ:EVLV
|
0.034x |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
0.414x |
|
Shuifa Energas Gas Co Ltd
SHG:603318
|
-0.019x |
|
SNT Dynamics Co Ltd
KO:003570
|
-0.026x |
|
Emerald Expositions Events Inc
NYSE:EEX
|
0.005x |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
N/A |
Annual Cash Flow Conversion Efficiency for Pulse Biosciences Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Pulse Biosciences Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see PLSE market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $114.86 Million | $-36.34 Million | -0.316x | +57.52% |
| 2023-12-31 | $44.36 Million | $-33.04 Million | -0.745x | -103.56% |
| 2022-12-31 | $-2.25 Million | $-47.01 Million | 20.913x | +1479.73% |
| 2021-12-31 | $35.69 Million | $-54.10 Million | -1.516x | +1.88% |
| 2020-12-31 | $22.89 Million | $-35.37 Million | -1.545x | -38.89% |
| 2019-12-31 | $30.74 Million | $-34.19 Million | -1.112x | -208.73% |
| 2018-12-31 | $66.33 Million | $-23.90 Million | -0.360x | -49.45% |
| 2017-12-31 | $45.99 Million | $-11.09 Million | -0.241x | +24.26% |
| 2016-12-31 | $25.30 Million | $-8.05 Million | -0.318x | -31.12% |
| 2015-12-31 | $13.67 Million | $-3.32 Million | -0.243x | -2153.35% |
| 2014-12-31 | $16.07 Million | $-173.14K | -0.011x | -- |
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Ca… Read more